Auxl historic stock price
To Board of Directors and Stockholders of Auxilium Pharmaceuticals, Inc.: Notes to Consolidated Financial Statements Report of Independent Registered Public Accounting FirmĬonsolidated Balance Sheets, December 31, 20Ĭonsolidated Statements of Operations, Years ended December 31, 2013, 2012, and 2011Ĭonsolidated Statements of Comprehensive Income (Loss), Years ended December 31, 2013, 2012, and 2011Ĭonsolidated Statements of Stockholders Equity, Year ended December 31, 2013Ĭonsolidated Statements of Stockholders Equity, Year ended December 31, 2012Ĭonsolidated Statements of Stockholders Equity, Year ended December 31, 2011Ĭonsolidated Statements of Cash Flows, Years ended December 31, 2013, 2012, and 2011
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned,ĪUXILIUM PHARMACEUTICALS, INC.
Auxl historic stock price pro#
Unaudited pro forma combined financial statements as of and for the nine months ended Septemand for the year ended December 31, 2013 Unaudited Consolidated Financial Statements of Auxilium Pharmaceuticals, Inc., including the Consolidated Balance Sheets as of Septemand Decemand the related Consolidated Statements of Operations,Ĭomprehensive Income (Loss), Stockholders Equity and Cash Flows for the nine months ended Septemand 2013 and accompanying notes The nine months ended September 30, 2014 and for the year ended December 31, 2013 are attached as Exhibit 99.3 and are included for your reference.Īudited Consolidated Financial Statements of Auxilium Pharmaceuticals, Inc., including the Consolidated Balance Sheets as of Decemand Decemand the related Consolidated Statements of Operations,Ĭomprehensive Income (Loss), Stockholders Equity and Cash Flows for the years ended December 31, 2013, 20 and accompanying notes The unaudited pro forma combined financial statements as of and for Statements of Auxilium Pharmaceuticals, Inc., including the Consolidated Balance Sheets as of September 30, 2014 and December 31, 2013 and the related Consolidated Statements of Operations, Comprehensive Income (Loss), StockholdersĮquity and Cash Flows for the nine months ended September 30, 20 and accompanying notes, are attached as exhibit 99.2. The years ended December 31, 2013, 20 and accompanying notes, are attached as exhibit 99.1. Pharmaceuticals, Inc., including the Consolidated Balance Sheets as of December 31, 2013 and December 31, 2012 and the related Consolidated Statements of Operations, Comprehensive Income (Loss), Stockholders Equity and Cash Flows for The audited Consolidated Financial Statements of Auxilium Subsidiary of HoldCo (Merger Sub), Merger Sub merged with and into Auxilium, with Auxilium continuing as the surviving entity and as an indirect wholly owned subsidiary of Endo (the Merger).Įndo is filing this amendment to the January 29, 2015 Current Report to include the financial information required by Item 9.01.įinancial statements of business acquired. Inc., a Delaware corporation and indirect subsidiary of Endo (HoldCo), and Avalon Merger Sub Inc., a Delaware corporation and direct Merger, dated November 17, 2014 (the Merger Agreement), among Auxilium, Endo, Endo U.S. (∺uxilium) on January 29, 2015 whereby, pursuant to the Amended and Restated Agreement and Plan of (∾ndo) filed a Current Report on Form 8-K to report that Endo completed the merger with Auxilium Pharmaceuticals, Inc. On January 29, 2015, Endo International plc Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))Ĭompletion of Acquisition or Disposition of Assets. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) If the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Name or former address, if changed since last report
Auxl historic stock price code#
Registrants telephone number, including area code 011-353. Minerva House, Simmonscourt Road, Ballsbridge, Dublin 4, Ireland (Exact Name of Registrant as Specified in Its Charter) Date of Report (Date of Earliest Event Reported): February 27, 2015 (January 29, 2015)